Systemic, portal and renal effects of terlipressin in patients with cirrhotic ascites: Pilot study

Journal of Gastroenterology and Hepatology (Australia)

Volumn 19, Issue 1, 2004, Pages 73-77

  Therapondos, George ^a   Stanley, Adrian J ^a   Hayes, Peter C ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Cirrhosis; Hepatorenal syndrome; Renal blood flow; Terlipressin

Indexed keywords

TERLIPRESSIN;

ADULT; ARTICLE; ASCITES; CLINICAL ARTICLE; DRUG EFFECT; DRUG MECHANISM; FEMALE; HEART OUTPUT; HEART RATE; HEMODYNAMICS; HUMAN; KIDNEY BLOOD FLOW; LIVER CIRRHOSIS; MALE; MEAN ARTERIAL PRESSURE; PRESSURE GRADIENT; PRIORITY JOURNAL; SODIUM URINE LEVEL; SYSTEMIC VASCULAR RESISTANCE; URINE VOLUME; VENOUS PRESSURE;

EID: 1642439103     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2004.03226.x     Document Type: Article

References (22)

1. Ioannou G, Doust J, Rockey DC. Terlipressin for acute esophageal variceal hemorrhage. Cochrane Database Syst. Rev. 2001: CD002147.
2. Le Moine O, el Nawar A, Jagodzinski R et al. Treatment with terlipressin as a bridge to liver transplantation in a patient with hepatorenal syndrome. Acta Gastroenterol. Belg. 1998; 61: 268-70.
3. Uriz J, Gines P, Cardenas A et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J. Hepatol. 2000; 33: 43-8.
4. Cervoni JP, Lecomte T, Cellier C et al. Terlipressin may influence the outcome of hepatorenal syndrome complicating alcoholic hepatitis. Am. J. Gastroenterol. 1997; 92: 2113-14.
5. Ganne-Carrie N, Hadengue A, Mathurin P, Durand F, Erlinger S, Benhamou JP. Hepatorenal syndrome. Long-term treatment with terlipressin as a bridge to liver transplantation. Dig. Dis. Sci. 1996; 41: 1054-6.
6. Alessandria C, Venon WD, Marzano A, Barletti C, Fadda M, Rizzetto M. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur. J. Gastroenterol. Hepatol. 2002; 14: 1363-8.
7. Ortega R, Gines P, Uriz J et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002; 36: 941-8.
8. Halimi C, Bonnard P, Bernard B et al. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur. J. Gastroenterol. Hepatol. 2002; 14: 153-8.
9. Moreau R, Durand F, Poynard T et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002, 122: 923-30.
10. Jalan R, Forrest EH, Redhead DN, Dillon JF, Hayes PC. Reduction in renal blood flow following acute increase in the portal pressure: evidence for the existence of a hepatorenal reflex in man? Gut 1997; 40: 664-70.
11. Hadengue A, Gadano A, Moreau R et al. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J. Hepatol. 1998; 29: 565-70.
12. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 1151-7.
13. Lenz K, Hortnagl H, Druml W et al. Beneficial effect of 8-ornithin vasopressin on renal dysfunction in decompensated cirrhosis. Gut 1989; 30: 90-6.
14. Lenz K, Druml W, Kleinberger G et al. Enhancement of renal function with ornipressin in a patient with decompensated cirrhosis. Gut 1985, 26: 1385-6.
15. Hirasawa A, Shibata K, Kotosai K, Tsujimoto G. Cloning, functional expression and tissue distribution of human cDNA for the vascular-type vasopressin receptor. Biochem. Biophys. Res. Commun. 1994; 203: 72-9.
16. Gulberg V, Luppa P, Pauletzki J, Paumgartner G, Gerbes AL. [Successful conservative therapy of hepatorenal syndrome with vasopressin-1-receptor antagonist ornipressin]. Z. Gastroenterol. 1998; 36: 1053-8. (In German.)
17. Evrard P, Ruedin P, Installe E, Suter PM. Low-dose ornipressin improves renal function in the hepatorenal syndrome. Crit. Care Med. 1994; 22: 363-6.
18. Guevara M, Gines P, Fernandez-Esparrach G et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma Volume expansion. Hepatology 1998; 27: 35-41.
19. Gulberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 1999; 30: 870-5.
20. Gadano A, Moreau R, Vachiery F et al. Natriuretic response to the combination of atrial natriuretic peptide and terlipressin in patients with cirrhosis and refractory ascites. J. Hepatol. 1997; 26: 1229-34.
21. Salo J, Gines A, Quer JC et al. Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome. J. Hepatol. 1996; 25: 916-23.
22. Lenz K, Hortnagl H, Druml W et al. Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis. Effects on renal hemodynamics and atrial natriuretic factor. Gastroenterology 1991; 101: 1060-7.